Lyterian Therapeutics

Lyterian Therapeutics is committed to developing transformative medicines for patients by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets. The company's name is derived from the Greek lutḗrios, meaning termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury, and Lyterian is inspired to learn from the logic that orchestrates homeostatic equilibria and drives healing, incorporating these learnings into medicine design. The company was co-founded by scientific founders including Aaron Gitler, Micha Rapé, Robert Tjian, Marius Wernig, and Ingrid Wertz, and is backed by The Column Group.